Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Debt to Equity (2016 - 2025)

IGC Pharma (IGC) has disclosed Debt to Equity for 15 consecutive years, with $0.02 as the latest value for Q3 2025.

  • Quarterly Debt to Equity fell 10.86% to $0.02 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $0.02 through Sep 2025, down 10.86% year-over-year, with the annual reading at $0.02 for FY2025, 13.12% up from the prior year.
  • Debt to Equity for Q3 2025 was $0.02 at IGC Pharma, down from $0.02 in the prior quarter.
  • The five-year high for Debt to Equity was $0.02 in Q2 2025, with the low at $0.0 in Q2 2021.
  • Average Debt to Equity over 5 years is $0.01, with a median of $0.01 recorded in 2023.
  • Peak annual rise in Debt to Equity hit 838.42% in 2021, while the deepest fall reached 81.41% in 2021.
  • Over 5 years, Debt to Equity stood at $0.01 in 2021, then soared by 53.31% to $0.01 in 2022, then soared by 98.03% to $0.02 in 2023, then surged by 40.45% to $0.02 in 2024, then decreased by 23.81% to $0.02 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.02, $0.02, and $0.02 for Q3 2025, Q2 2025, and Q1 2025 respectively.